Arbutus Biopharma Stock Dips on Dropped 'Buy' Rating

B. Riley cut its rating on outperforming ABUS to 'neutral'

Jul 6, 2018 at 10:06 AM
facebook twitter linkedin

Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) are sinking this morning, as traders react to negative analyst attention. Specifically, B. Riley downgraded ABUS stock to "neutral" from "buy," saying the shares have already priced in royalty opportunities from Alnylam's (ALNY) patisiran drug, and noting ABUS' outperformance already this year. Just yesterday, in fact, Arbutus stock notched a two-year high of $9.15, but today is down 9.6% to trade at $8.25.

Even with this morning's pullback, ABUS still sports a year-over-year gain of more than 120%. Further, the drug stock is still up more than 17% this week, on pace for its best week since September -- not to mention this was a shortened holiday week. As such, the equity's 14-day Relative Strength Index (RSI) stood at a lofty 83 at yesterday's close, well into overbought territory.

It's not surprising to find that most analysts are in the bullish camp. Arbutus Biopharma stock boasts three "strong buy" endorsements, compared to one tepid "hold." However, short sellers are beginning to circle the outperformer. Short interest on ABUS surged 19.3% in the most recent reporting period, and now represents about four sessions' worth of pent-up buying demand, at the stock's average pace of trading.


Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Best stocks for October and worst stocks for October


Special Offers from Schaeffer's Trading Partners